Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
NCT06377930
Recruiting
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Focal Onset Seizures
Register for Updates
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT06275126
Recruiting
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participa... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
03/07/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT05822583
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Yale University (Site 025-001), New Haven, Connecticut
Conditions: COVID-19
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Yale University / Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Pre-IVF Treatment with a GnRH Antagonist in Women with Endometriosis_temp
NCT06375811
Recruiting
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
03/06/2025
Locations: Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences, New Haven, Connecticut
Conditions: Infertility, Endometriosis
Register for Updates
Biliary Atresia Research Network Northeast
NCT06184971
Recruiting
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia. Overall, investigators aim to evaluate which specific factors contribute to improved patient outcomes, to help guide potential improvements in patient care and resource utilization.
Gender:
ALL
Ages:
12 years and below
Trial Updated:
03/06/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Biliary Atresia
Register for Updates
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
NCT06111768
Recruiting
The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/06/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Cardiorenal Syndrome
Register for Updates
AMPK-activation by Metformin in FSGS: AMP-FSGS
NCT06090227
Recruiting
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/06/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
NCT05106387
Recruiting
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2025
Locations: Yale University of Medicine, New Haven, Connecticut
Conditions: Chronic Kidney Disease (CKD)
Register for Updates
In Vivo Study of THC-induced Immune-genome Changes At Single Cell Solution in HIV-infected Humans
NCT04920539
Recruiting
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: HIV Infections, Healthy
Register for Updates
Study Of ATRN-119 In Patients With Advanced Solid Tumors
NCT04905914
Recruiting
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/06/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
Ertugliflozin in Chronic Heart Failure
NCT04438213
Recruiting
The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Heart Failure
Register for Updates